Privacy and the 100,000 Genome Project
By Edward Hockings and Lewis Coyne,
The Guardian
| 03. 10. 2015
Untitled Document
With the UK launch of 23andMe’s home DNA testing kit, the legalisation of mitochondrial DNA transfer, and the 100,000 Genome Project underway, optimism abounds about the science of genetics delivering on its early promise. But there is also cause for greater caution and oversight than some biotechnology enthusiasts would like to admit.
These developments are taking place with insufficient regard for their social and ethical implications. We can, however, be sure that the policies and regulatory frameworks currently being enacted will shape future decisions. A balance needs to be struck between the pro-R&D agenda that is driving a permissive regulatory regime, and sensitivity towards concerns about genetic technologies that public consultation, if properly conducted, can alert us to. It is in the public interest that there is wider discussion of the full implications of recent developments.
The 100,000 Genome Project is a case in point. The collection and sequencing of 100,000 individuals’ genetic information is intended to constitute the first phase of what will be a national genomic database. The ‘50 million Genome Project’ will include the genomes...
Related Articles
By Annika Inampudi, Science | 07.10.2025
Before a baby in the United States reaches a few days old, doctors will run biochemical tests on a few drops of their blood to catch certain genetic diseases that need immediate care to prevent brain damage or other serious...
By Geoffrey A. Fowler, The Washington Post | 07.17.2025
Nearly 2 million people protected their privacy by deleting their DNA from 23andMe after it declared bankruptcy in March. Now it’s back with the same person in charge — and I still don’t trust it.
Nor do the attorneys general...
By Elizabeth Dwoskin and Yeganeh Torbati, The Washington Post | 07.16.2025
A group of well-heeled, 30-something women sat down to dinner last spring at a table set with pregnancy-friendly mocktails and orchids, ready to hear a talk about how to optimize their offspring.
Noor Siddiqui, the founder of an embryo-screening start-up...
By Suzanne O'Sullivan, New Scientist | 07.09.2025
Rare diseases are often hard to spot. They can evade detection until irreversible organ damage or disability has already set in. Last month, in the hope of preventing just this type of harm, the UK’s health secretary, Wes Streeting, announced...